Provided are methods for activating an antigen-presenting cell and eliciting an immune response by inducing an inducible pattern recognition receptor adapter, or adapter fragment, and CD40 activity. Also provided are nucleic acid compositions comprising sequences coding for chimeric proteins that include an inducible CD40 peptide and an inducible pattern recognition receptor adapter or adapter fragment.

The present disclosure provides isolated laminin-421, methods for making recombinant laminin-421, and host cells that express recombinant laminin-421. The present disclosure also provides nucleic acid sequences encoding full length human laminin 2 chain, expression vectors and host cells thereof.

Disclosed herein, in aspects, are compositions, methods, kits, and systems relating to efficient delivery of freights (e.g., therapeutic freights) into cells, for instance, for in vivo delivery.

The subject invention pertains methods for the ectopic expression of a transmembrane protein lacking plasma membrane expression in a heterologous cell line. In embodiments, transmembrane proteins Fyn-TMC1 and/or Fyn-TMC2 are fused to a membrane-anchoring motif, a Fyn lipidation tag, which provides a signal for myristoylation and palmitoylation, allowing further research on these proteins, including but not limited to their function, structure, and drug screening.

Provided herein are anti-CD24 antibodies that selectively bind human CD24 expressed in cancer cells, but not human CD24 expressed in non-cancerous cells, and the use of such antibodies in cancer therapy.

Disclosed herein are compositions, methods, kits, and systems relating to efficient delivery of cargos (e.g., therapeutic cargos) into cells, for instance, for in vivo delivery. The present disclosure provides lipid-containing particles (e.g., virus-like particles) for delivering therapeutic cargos. The present disclosure also provides polynucleotides encoding the lipid-containing particles provided herein, which may be useful for producing said lipid-containing particles. Also provided are methods for editing nucleic acid molecules in cells using the lipid-containing particles provided herein, as well as cells and kits comprising the lipid-containing particles.

Provided herein are cells expressing a first and a second chimeric protein in the cell membrane. Such cells can solve expression problems of CAR constructs caused by these CAR construct's ability to recognize unwanted internal epitopes or exhibiting unwanted signalling due to misfolding/scFv aggregation. The first chimeric protein comprises an extracellular antigen binding unit and an intracellular dimerization domain. The second chimeric protein comprises a lipid anchoring domain, an intracellular dimerization domain and a signaling domain. Accordingly, the expression of the two proteins allows them to translocate to the cell membrane without much interference and subsequently gain signaling capacity when colocalized at the cell membrane.

Provided herein are novel synthetic pathway activators comprising multimerization regions, transmembrane domains, and intracellular signaling domains.

Non-human animal genomes, non-human animal cells, and non-human animals comprising a humanized TRKB locus and methods of making and using such non-human animal genomes, non-human animal cells, and non-human animals are provided. Non-human animal cells or non-human animals comprising a humanized TRKB locus express a human TRKB protein or a chimeric transthyretin protein, fragments of which are from human TRKB. Methods are provided for using such non-human animals comprising a humanized TRKB locus to assess in vivo efficacy of human-TRKB-targeting reagents such as nuclease agents designed to target human TRKB.

The present disclosure provides synthetic modular polypeptide libraries and nucleic acids encoding such synthetic modular polypeptide libraries. Also provided are methods of making synthetic modular polypeptide libraries and nucleic acids encoding synthetic modular polypeptide libraries. Methods of screening a synthetic modular polypeptide library to identify a selected phenotype associated with a member of a synthetic modular polypeptide library are also provided where such methods find use in both in vitro and in vivo assays.